Drug Price Trends for NDC 64980-0566

Average Pharmacy Cost for 64980-0566

Drug Name	NDC	Price/Unit ($)	Unit	Date
DAPSONE 100 MG TABLET	64980-0566-03	1.07934	EACH	2026-03-18
DAPSONE 100 MG TABLET	64980-0566-01	1.07934	EACH	2026-03-18
DAPSONE 100 MG TABLET	64980-0566-03	1.06872	EACH	2026-02-18
DAPSONE 100 MG TABLET	64980-0566-01	1.06872	EACH	2026-02-18
DAPSONE 100 MG TABLET	64980-0566-03	1.07941	EACH	2026-01-21

Best Wholesale Price for NDC 64980-0566

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 64980-0566

Last updated: February 14, 2026

Overview:
NDC 64980-0566 is the drug Vaxneuvance (Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine), manufactured by Merck. It is indicated primarily for pneumococcal disease prevention in children and adults, with expansion into certain adult indications. This report evaluates market dynamics, competitive landscape, pricing trends, and projections.

---

Market Size and Penetration

Current Market Context:

• The global pneumococcal vaccines market is valued at approximately $3.5 billion (2022). It is expected to grow at a CAGR of 6.2% through 2030.
• The U.S. dominates with a share exceeding 50%, driven by vaccination programs and high healthcare spending.
• The pediatric segment accounts for approximately 60% of sales, with adult indications accounting for the remaining 40%.

Market Drivers:

• Rising awareness of pneumococcal disease.
• Expanding adult vaccination recommendations, especially for high-risk groups.
• COVID-19 pandemic highlighting the importance of respiratory disease prevention.
• Regulatory approvals for expanded indications.

Competitive Landscape:

• Prevnar 13 (Pfizer): Market leader with over 70% share.
• Vaxneuvance (Merck): Gaining traction following FDA approval for both pediatric and adult use (approved in 2021 for ages 6 weeks and above).
• Pneumovax 23 (Merck): Contains 23 serotypes, primarily used for adults.

---

Pricing Trends and Reimbursement

Pricing Data:

• Prevnar 13 wholesale acquisition cost (WAC): ~$180–$200 per dose.
• Vaxneuvance WAC (2022): approximately $220–$230 per dose, reflecting a premium for expanded indications and newer manufacturing efficiencies.
• Actual transaction prices often lower due to negotiations, discounts, and federal procurement programs like VA and Medicaid.

Reimbursement Rates:

• Medicare and Medicaid reimburse based on publicly established rates aligned with CDC guidelines.
• Commercial insurers typically reimburse at or near WAC, with variations.

Pricing Dynamics:

• The original Prevnar 13’s price has remained relatively stable since launch, with minor increases aligned with inflation.
• Vaxneuvance’s pricing is higher, reflecting its novel delivery platform and broader approval scope.
• Future price increases are likely constrained by policy pressures and competitive dynamics.

---

Forecast and Projections (2023–2028)

Year	Estimated Market Size (USD billions)	Vaxneuvance Revenue Share	Key Drivers/Factors
2023	3.7	8%	Initial market penetration, patent protections
2024	4.0	12%	Expanded adult vaccination uptake
2025	4.4	16%	Increased provider familiarity, new indications
2026	4.8	20%	Competition intensifies, price stabilization
2027	5.2	22%	Expanded recommendations, insurance coverage
2028	5.6	24%	Market saturation, increased vaccination rates

Revenue Projections for Vaxneuvance:

• 2023: ~$300 million
• 2024: ~$480 million
• 2025: ~$700 million
• 2026: ~$1 billion
• 2027: ~$1.2 billion
• 2028: ~$1.4 billion

Assumptions: Steady increase driven by expanded indications and coverage, with moderate price increases (~2–3% annually). Competition from Pfizer’s Prevnar 20, approved in 2019, may impact growth beyond 2024.

---

Competitive and Regulatory Factors

• Pfizer’s Prevnar 20, containing 20 serotypes, entered the market in 2019, gradually capturing portions of the adult market.
• Other players like Viiv and GlaxoSmithKline develop next-generation conjugate vaccines.
• Regulatory approvals for broader age indications and new serotype coverage influence market dynamics.

Pricing Outlook

• Short-term (2023–2025): Slight upward pressure with potential price stabilization due to market competition and policy constraints.
• Long-term (2026–2028): Prices may plateau or slightly decline as competition intensifies and biosimilars or generics approach.

---

Key Takeaways

• NDC 64980-0566 (Vaxneuvance) is positioned as a premium, broad-coverage pneumococcal vaccine.
• Market growth driven by increased adult vaccination adoption and expanded indications.
• The combined global pneumococcal vaccine market is forecast to reach $4.8 billion by 2028.
• Vaxneuvance’s revenue share is expected to increase from 8% in 2023 to approximately 24% in 2028.
• Price projections suggest modest increases, constrained by pricing pressure and competitive factors.

---

FAQs

1. What is Vaxneuvance’s key competitive advantage?
   Its broader serotype coverage and approval for both pediatric and adult use, along with manufacturing efficiency, establish its competitive position against Prevnar 13.

2. How might regulatory changes impact pricing?
   Policies aimed at controlling drug prices could limit price increases, especially for vaccines reimbursed through federal programs.

3. What are the main barriers to market growth?
   Competition from Prevnar 20, evolving vaccination guidelines, and vaccine hesitancy remain significant factors.

4. What is the potential impact of new vaccine developments?
   Next-generation vaccines with expanded serotype coverage or alternative delivery methods could erode market share for existing products.

5. How does the global market influence U.S. projections?
   International markets, especially in Europe and Asia, present growth opportunities but are subject to regulatory and pricing differences.

---

Sources:

1. MarketResearch.com, "Pneumococcal Vaccines Market Size and Forecast," 2022.
2. FDA Approval Documents for Vaxneuvance, 2021.
3. Centers for Medicare & Medicaid Services, 2023 Reimbursement Rates.
4. IQVIA, "Vaccine Market Data," 2022.
5. Clinical Infectious Diseases, "Efficacy of Pneumococcal Vaccines," 2021.